San Diego, CA -- (SBWIRE) -- 12/19/2017 -- Zymeworks Inc is under investigation over potential securities laws violations in connection with certain financial statements. The investigation was announced for investors in NYSE:ZYME shares.

Investors who purchased shares of Zymeworks Inc (NYSE:ZYME) should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements by Zymeworks Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. Zymeworks Inc reported that its annual Total Revenue rose from $9.66 million in 2015 to $11.01 million in 2016. On April 28, 2017, Zymeworks Inc sold 4.5 million shares of stock in its initial public stock offering (the "IPO"), raising $58.50 million in new capital. However, since the IPO, Zymeworks Inc stock declined to as low as $7.26 per share.

Those who purchased shares of Zymeworks Inc (NYSE:ZYME) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com